You are here

Lexaria Bioscience Corp.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Diversified Industries
Symbol: 
LXX
CSE Index: 
Currency: 

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

 

You are here

Lexaria Bioscience Corp. (LXX)

SEDAR Information

Company Info

Address
#100 - 740 McCurdy Rd.,
Kelowna, BC V1X 2P7
Canada
Phone
1-250-765-6424
Fax
1-250-765-2599
Email
cbunka@lexariabioscience.com
Website
http://www.lexariabioscience.com
Listing date
Wednesday, October 28, 2009
Transfer Agent
Computershare Investor Services Inc.
Auditor
Davidson & Company LLP

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
3,001,476
Reserved for Issuance: 
10,285,820

Company Officers

Chris Bunka, CEO
John Docherty, President
Allan Spissinger CPA, CA, CFO

Bulletins

11/01/2021

2021-0112 –Consolidation - Lexaria Bioscience Corp. (LXX)

Le 11 janvier/January 2021

Lexaria Bioscience Corp. has announced a consolidation of its issued and outstanding common shares. At the rate of one (1) new share for each thirty (30) shares held.

The consolidation will be effected at 4:30 p.m. (EST) on January 11, 2021 with the shares trading on a post-consolidated basis on January 12, 2021.

Upon completion of the split, there will be approximately 3,001,476 shares issued and outstanding.

Advertisement

Publicité

Latest CSE News

Upcoming Events